CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PR Newswire Biotech
Original article

Exonate Becomes Foventa Therapeutics

FOV407Positive
AI Analysis

Summary

Exonate rebranded as Foventa Therapeutics to reflect its focus on clinical development of FOV407 for non-proliferative diabetic retinopathy, a compound that demonstrated vascular leakage suppression in earlier trials.

Clinical Trial Data

Primary Endpoint

Met

Importance:2/10
Sentiment:
0.50
company_rebrandclinical_developmentdiabetic_retinopathyophthalmology

Read the original article

Published by PR Newswire Biotech on September 1, 2026 9:30 AM

Read Original